Organovo's Sharon Presnell, Ph.D., presents "Shaping the Future of Medicine…from better drugs to tissue on-demand"

1. Shaping
the
Future
of
Medicine…
from
be6er
drugs
to
8ssue
on-­‐demand
Sharon
Presnell,
Ph.D.
Chief
Technology
Officer
© Copyright 2013, Organovo Holdings, Inc. This report is solely for the use of intended audience. No part
of it may be circulated, quoted, or reproduced for distribution outside the organization without prior written
approval from Organovo Holdings, Inc.

2. SAFE HARBOR STATEMENT
2
NYSEMKT:
ONVO
©Copyright
2013
Organovo,
Inc.
Any
statements
contained
in
this
presentaAon
that
do
not
describe
historical
facts
may
consAtute
forward-­‐looking
statements
as
that
term
is
defined
in
the
Private
SecuriAes
LiAgaAon
Reform
Act
of
1995.
Any
forward-­‐looking
statements
contained
herein
are
based
on
current
expectaAons,
but
are
subject
to
a
number
of
risks
and
uncertainAes.
The
factors
that
could
cause
actual
future
results
to
differ
materially
from
current
expectaAons
include,
but
are
not
limited
to,
risks
and
uncertainAes
relaAng
to
the
Company's
ability
to
develop,
market
and
sell
products
based
on
its
technology;
the
expected
benefits
and
efficacy
of
the
Company’s
products
and
technology;
the
availability
of
substanAal
addiAonal
funding
for
the
Company
to
conAnue
its
operaAons
and
to
conduct
research
and
development,
clinical
studies
and
future
product
commercializaAon;
and,
the
Company's
business,
research,
product
development,
regulatory
approval,
markeAng
and
distribuAon
plans
and
strategies.
These
and
other
factors
are
idenAfied
and
described
in
more
detail
in
our
filings
with
the
SEC,
including
our
annual
report
for
the
period
ended
December
31,
2012
on
Form
10-­‐K
and
our
current
reports
filed
on
Form
8K.
We
do
not
undertake
to
update
these
forward-­‐looking
statements
made
by
us.

3. 3

4. 4
KIDNEY
DONORS
Data
Sources:
• USRDS
• UNOS
KIDNEY
TRANSPLANT
WAITLIST

5. 5
KIDNEY
DONORS
Data
Sources:
• USRDS
• UNOS
KIDNEY
TRANSPLANT
WAITLIST
PEOPLE
WITH
END-­‐STAGE
RENAL
FAILURE
PEOPLE
WITH
MID-­‐
TO
LATE-­‐STAGE
CKD

6. Target
Discovery
Lead
ID
Lead
Op<miza<on
ADMET
Development
Registra<on
and
approval
6
Living human cells are widely used
in drug development and regenerative medicine
©Copyright
2013
Organovo,
Inc.
CELL-­‐BASED
ASSAYS
CELLS
&
TISSUES
AS
THERAPEUTIC
AGENTS
From
Zreiqat
et
al.,
Biomaterials
2010
31:3175

7. 7
(NYSEMKT:
ONVO)
• Founded
in
2007,
based
on
proprietary
bio-­‐prinAng
technology
developed
at
the
University
of
Missouri
with
a
$5M
NaAonal
Science
FoundaAon
grant
• Based
in
San
Diego
in
a
15,000
sq
i
facility
with
dedicated
bioprinAng
/
Assue
culture
and
analyAcal
laboratories
• A
leader
in
“3D
prinAng”
of
human
Assue
targeAng
in
vitro
and
in
vivo
applicaAons
2012
©Copyright
2013
Organovo,
Inc.

8. 8

9. Peripheral
Nerve
Lung
Bone
Blood
Vessel
Skeletal
Muscle
Liver
Cardiac
©Copyright
2013
Organovo,
Inc.

10. Organovo’s 3D Human Liver Tissue Array
Standard
Corning
TranswellTM
Plates
• Automated,
reproducible
• Represents
naAve
human
Assue
10
©Copyright
2013
Organovo,
Inc.
NATIVE
LIVER
TISSUE
ONVO
3D
LIVER
TISSUE
LIVER
CELLS
ON
3D
SCAFFOLD
From
Mat
Sci
Eng
2012
C32:310

11. Organovo’s 3D Human Liver Tissue Array
• Automated,
reproducible
• Represents
naAve
human
Assue
• Exhibits
superior
funcAon
11
©Copyright
2013
Organovo,
Inc.
ONVO
Standard
3D
2D
LIVER-­‐SPECIFIC
PROTEIN
SECRETION
(ng
Albumin
/
mL
/
million
cells)
*
p
<
0.001

12. Enabling blood supply…
A critical step in building implantable tissues
From
establishing
microvascular
networks…
…to
simple
blood
vessels
…to
branched
vascular
trees
Vascular
Networks
(brown)
in
bioprinted
human
Assue
Bioprinted
Branched
Vessel

13. 13
©Copyright
2013
Organovo,
Inc.
Partner Companies & Institutions